GlycoMimetics Inc (GLYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlycoMimetics Inc (GLYC) has a cash flow conversion efficiency ratio of -1.513x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.11 Billion) by net assets ($3.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GLYC net asset quality score to measure how much of total assets are equity-financed.
GlycoMimetics Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GlycoMimetics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
GlycoMimetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoMimetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Global Smaller Companies Trust Plc
LSE:GSCT
|
0.005x |
|
WISDOM ED.INTL.HLD.HD-01
F:5Q4
|
N/A |
|
California Nanotechnologies Corp
V:CNO
|
-0.078x |
|
Thai Poly Acrylic Public Company Limited
BK:TPA
|
-0.006x |
|
KINGFISH COMPANY EO -01
F:93G
|
N/A |
|
Taranis Resources Inc
V:TRO
|
-0.019x |
|
Ni Hsin Resources Bhd
KLSE:7215
|
-0.015x |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
-0.116x |
Annual Cash Flow Conversion Efficiency for GlycoMimetics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of GlycoMimetics Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see GlycoMimetics Inc (GLYC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.31 Million | $-31.10 Million | -5.853x | -544.56% |
| 2023-12-31 | $38.41 Million | $-34.88 Million | -0.908x | +16.10% |
| 2022-12-31 | $42.93 Million | $-46.46 Million | -1.082x | -53.61% |
| 2021-12-31 | $81.60 Million | $-57.49 Million | -0.704x | -130.19% |
| 2020-12-31 | $128.22 Million | $-39.24 Million | -0.306x | +9.21% |
| 2019-12-31 | $154.20 Million | $-51.98 Million | -0.337x | -59.85% |
| 2018-12-31 | $205.46 Million | $-43.33 Million | -0.211x | +15.20% |
| 2017-12-31 | $119.70 Million | $-29.77 Million | -0.249x | +70.47% |
| 2016-12-31 | $35.30 Million | $-29.73 Million | -0.842x | -313.57% |
| 2015-12-31 | $40.47 Million | $-8.24 Million | -0.204x | -141.64% |
| 2014-12-31 | $50.80 Million | $-4.28 Million | -0.084x | +98.42% |
| 2013-12-31 | $2.91 Million | $-15.54 Million | -5.345x | -539.33% |
| 2012-12-31 | $12.53 Million | $-10.47 Million | -0.836x | -151.03% |
| 2011-12-31 | $8.46 Million | $13.85 Million | 1.638x | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.